<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03257761</url>
  </required_header>
  <id_info>
    <org_study_id>0S-16-18</org_study_id>
    <secondary_id>NCI-2017-01432</secondary_id>
    <secondary_id>0S-16-18</secondary_id>
    <secondary_id>P30CA014089</secondary_id>
    <nct_id>NCT03257761</nct_id>
  </id_info>
  <brief_title>Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer</brief_title>
  <official_title>A Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients With Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and Cholangiocarcinoma/Gallbladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Van Andel Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase Ib trial studies the side effects and best dose of guadecitabine and how well it&#xD;
      works when given together with durvalumab in treating patients with liver, pancreatic, bile&#xD;
      duct, or gallbladder cancer that has spread to other places in the body. Guadecitabine may&#xD;
      stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.&#xD;
      Monoclonal antibodies, such as durvalumab, may block tumor growth in different ways by&#xD;
      targeting certain cells. Giving guadecitabine and durvalumab may work better in treating&#xD;
      patients with liver, pancreatic, bile duct, or gallbladder cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the dose limiting toxicities and determine the maximum tolerated&#xD;
      dose/recommended phase 2 dose of the combination of guadecitabine and durvalumab. (Dose&#xD;
      escalation part) II. To evaluate the objective response rate (per Response Evaluation&#xD;
      Criteria in Solid Tumors [RECIST] 1.1) for the combination of guadecitabine and durvalumab in&#xD;
      hepatocellular carcinoma, pancreatic cancer and cholangiocarcinoma cohorts, respectively.&#xD;
      (Expansion part)&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To describe the safety and tolerability of the combination of guadecitabine and&#xD;
      durvalumab.&#xD;
&#xD;
      II. To estimate the progression-free and overall survival of patients with advanced&#xD;
      hepatocellular carcinoma (HCC), pancreatic cancer and biliary cancers treated with the&#xD;
      combination of guadecitabine and durvalumab.&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. Correlate programmed cell death ligand 1 (PD-L1) and programmed cell death protein 1 (PD1)&#xD;
      expression on various cells within tumor samples and anti-tumor effect (response rate and&#xD;
      survival).&#xD;
&#xD;
      II. Correlate effector T cells (Teff)/regulatory T cells (Treg) ratio in the tumor and&#xD;
      anti-tumor effect.&#xD;
&#xD;
      III. Correlate granulocytic and monocytic myeloid-derived suppressor cells (MDSCs) level in&#xD;
      the peripheral blood using fluorescence-activated cell sorting (FACS) and anti-tumor effect.&#xD;
&#xD;
      IV. Evaluate changes in inflammatory T cell signatures pre and post treatment and potential&#xD;
      associations with anti-tumor effect.&#xD;
&#xD;
      V. Assess the induction, activation, expansion and tumor infiltration of tumor&#xD;
      neo-epitope-specific T cells.&#xD;
&#xD;
      VI. Explore changes in gene methylation and expression with anti-tumor effect, with&#xD;
      particular emphasis on the ancestry-informative marker (AIM) gene panel.&#xD;
&#xD;
      VII. Correlate immunologic changes in pre- and post-treatment peripheral blood mononuclear&#xD;
      cell (PBMCs) and anti-tumor effect.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of guadecitabine.&#xD;
&#xD;
      Patients receive guadecitabine subcutaneously (SC) once daily (QD) on days 1-5 and durvalumab&#xD;
      intravenously (IV) over 60 minutes on day 8. Courses repeat every 28 days in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 2 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 7, 2018</start_date>
  <completion_date type="Anticipated">March 2, 2024</completion_date>
  <primary_completion_date type="Actual">March 2, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 56 days</time_frame>
    <description>Graded according to Common Terminology Criteria for Adverse Events version 4.03.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor response (dose expansion)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be calculated by the percentage of patients having complete or partial response among all patients who have been treated at maximum tolerated dose/recommended phase II dose in each cohort. Will be assessed according to Response Evaluation Criteria in Solid Tumors (RECIST).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From start of treatment until death due to any cause, assessed up to 2 years</time_frame>
    <description>Kaplan-Meier curves will be used to show overall survival in each cohort. Median overall survival and 95% confidence intervals will be derived from Kaplan-Meier curves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From start of treatment to time of progression per RECIST 1.1 or death whichever comes first, assessed up to 2 years</time_frame>
    <description>Kaplan-Meier curves will be used to show progression-free survival in each cohort. Median progression-free survival and 95% confidence intervals will be derived from Kaplan-Meier curves.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Extrahepatic Bile Duct Adenocarcinoma, Biliary Type</condition>
  <condition>Gallbladder Adenocarcinoma, Biliary Type</condition>
  <condition>Metastatic Pancreatic Adenocarcinoma</condition>
  <condition>Recurrent Cholangiocarcinoma</condition>
  <condition>Recurrent Gallbladder Carcinoma</condition>
  <condition>Recurrent Hepatocellular Carcinoma</condition>
  <condition>Recurrent Intrahepatic Cholangiocarcinoma</condition>
  <condition>Recurrent Pancreatic Carcinoma</condition>
  <condition>Stage III Gallbladder Cancer AJCC V7</condition>
  <condition>Stage III Hepatocellular Carcinoma AJCC v7</condition>
  <condition>Stage III Intrahepatic Cholangiocarcinoma AJCC v7</condition>
  <condition>Stage III Pancreatic Cancer AJCC v6 and v7</condition>
  <condition>Stage IIIA Gallbladder Cancer AJCC v7</condition>
  <condition>Stage IIIA Hepatocellular Carcinoma AJCC v7</condition>
  <condition>Stage IIIB Gallbladder Cancer AJCC v7</condition>
  <condition>Stage IIIB Hepatocellular Carcinoma AJCC v7</condition>
  <condition>Stage IIIC Hepatocellular Carcinoma AJCC v7</condition>
  <condition>Stage IV Gallbladder Cancer AJCC v7</condition>
  <condition>Stage IV Hepatocellular Carcinoma AJCC v7</condition>
  <condition>Stage IV Pancreatic Cancer AJCC v6 and v7</condition>
  <condition>Stage IVA Gallbladder Cancer AJCC v7</condition>
  <condition>Stage IVA Hepatocellular Carcinoma AJCC v7</condition>
  <condition>Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7</condition>
  <condition>Stage IVB Gallbladder Cancer AJCC v7</condition>
  <condition>Stage IVB Hepatocellular Carcinoma AJCC v7</condition>
  <condition>Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7</condition>
  <condition>Unresectable Gallbladder Carcinoma</condition>
  <condition>Unresectable Pancreatic Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (guadecitabine, durvalumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive guadecitabine SC QD on days 1-5 and durvalumab IV over 60 minutes on day 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (guadecitabine, durvalumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guadecitabine</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (guadecitabine, durvalumab)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of&#xD;
             0-1&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1.5 x 10^9/L (&gt; 1500 per mm^3) except for patients&#xD;
             with HCC for whom ANC &gt;= 1000 per mm^3 is allowed&#xD;
&#xD;
          -  Platelet count &gt;= 100 x 10^9/L (&gt; 100,000 per mm^3), except for patients with HCC for&#xD;
             whom a platelet count &gt; 60,000 per mm^3 is allowed&#xD;
&#xD;
          -  Hemoglobin &gt;= 8.0 g/dL; if patients have a hemoglobin level below 8, blood transfusion&#xD;
             is allowed to meet the eligibility criteria as long as post transfusion hemoglobin is&#xD;
             maintained at &gt;= 8.0 g/dL for 7 days or longer&#xD;
&#xD;
          -  Aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) and&#xD;
             alanine aminotransaminase (ALT)/serum glutamate pyruvate transaminase (SGPT) =&lt; 2.5 x&#xD;
             institutional upper limit of normal unless liver metastases are present or unless&#xD;
             patient is known to have chronic liver disease (hepatitis) in which case AST and ALT&#xD;
             must be =&lt; 5 x institutional upper limit of normal (IULN)&#xD;
&#xD;
          -  Serum bilirubin =&lt; 2.5 x institutional upper limit of normal (ULN)&#xD;
&#xD;
          -  Serum albumin &gt;= 2.5 g/dL&#xD;
&#xD;
          -  Serum creatinine clearance (CL) &gt; 40 mL/min by the Cockcroft-Gault formula or by&#xD;
             24-hour urine collection for determination of creatinine clearance&#xD;
&#xD;
          -  Women of child-bearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control; abstinence) prior to study entry, for&#xD;
             the duration of study participation, and for 90 days following completion of therapy;&#xD;
             should a woman become pregnant or suspect she is pregnant while participating in this&#xD;
             study, she should inform her treating physician immediately&#xD;
&#xD;
               -  A female of child-bearing potential is any woman (regardless of sexual&#xD;
                  orientation, having undergone a tubal ligation, or remaining celibate by choice)&#xD;
                  who meets the following criteria:&#xD;
&#xD;
                    -  Has not undergone a hysterectomy or bilateral oophorectomy; or&#xD;
&#xD;
                    -  Has not been naturally postmenopausal for at least 12 consecutive months&#xD;
                       (i.e., has had menses at any time in the preceding 12 consecutive months)&#xD;
&#xD;
               -  Female subjects must either be of non-reproductive potential (ie, post-menopausal&#xD;
                  by history: &gt;= 60 years old and no menses for &gt;= 1 year without an alternative&#xD;
                  medical cause; OR history of hysterectomy, OR history of bilateral tubal&#xD;
                  ligation, OR history of bilateral oophorectomy) or must have a negative serum&#xD;
                  pregnancy test upon study entry&#xD;
&#xD;
          -  Ability to understand a written informed consent&#xD;
&#xD;
          -  Signed written informed consent and Health Insurance Portability and Accountability&#xD;
             Act (HIPAA) obtained from the subject prior to performing any protocol-related&#xD;
             procedures, including screening evaluations&#xD;
&#xD;
          -  Subject is willing and able to comply with the protocol for the duration of the study&#xD;
             including undergoing treatment and scheduled visits and examinations including follow&#xD;
             up&#xD;
&#xD;
          -  Patients must have measurable disease as defined by RECIST 1.1 criteria&#xD;
&#xD;
          -  Hepatocellular carcinoma cohort specific criteria:&#xD;
&#xD;
               -  Patients must have a histologically proven diagnosis of hepatocellular carcinoma&#xD;
                  that is not amenable to curative surgical therapeutic options&#xD;
&#xD;
               -  Patients must not be good candidates for locoregional therapy as determined by&#xD;
                  the investigator (ie diffuse multifocal disease, vascular involvement, etc)&#xD;
&#xD;
               -  Patients must have had evidence of radiologic progression on sorafenib or have&#xD;
                  had intolerance to sorafenib as defined by the recurrence of clinically&#xD;
                  significant toxicities despite a minimum of one dose reduction and appropriate&#xD;
                  supportive care; patients who refuse sorafenib are eligible with documentation of&#xD;
                  refusal by the treating physician&#xD;
&#xD;
               -  Patients may have received other treatment for HCC such as embolization,&#xD;
                  chemoembolization, intra-arterial chemotherapy, ethanol injection, ablative&#xD;
                  therapy, cryosurgery, or other locoregional or targeted therapy&#xD;
&#xD;
               -  Patients must have a Child Pugh score of 7 points or less&#xD;
&#xD;
               -  International normalized ratio (INR) =&lt; 2.3 or prothrombin time =&lt; 6 seconds&#xD;
                  above control&#xD;
&#xD;
               -  Patients with hepatitis B infection must be on appropriate anti-viral therapy&#xD;
&#xD;
          -  Cholangiocarcinoma cohort specific criteria:&#xD;
&#xD;
               -  Patients must have histologically or cytologically documented carcinoma primary&#xD;
                  to the intra- or extra-hepatic biliary system or gall bladder with clinical&#xD;
                  and/or radiologic evidence of unresectable, locally advanced or metastatic&#xD;
                  disease; patients with ampullary carcinoma are not eligible&#xD;
&#xD;
               -  Patients must have failed at least one (but no more than 2) prior line of&#xD;
                  systemic therapy in the advanced disease setting&#xD;
&#xD;
               -  Patients who received adjuvant chemotherapy and had evidence of disease&#xD;
                  recurrence within 6 months of completion of the adjuvant treatment are also&#xD;
                  eligible; in this case, the adjuvant therapy will count as the minimum required&#xD;
                  one prior line of therapy; if patient received adjuvant treatment and had disease&#xD;
                  recurrence after 6 months, patients will only be eligible after failing one&#xD;
                  regimen of systemic chemotherapy used to treat the (unresectable or metastatic)&#xD;
                  disease recurrence&#xD;
&#xD;
               -  If the patient has had decompression of the biliary tree within the last 14 days,&#xD;
                  stability of the bilirubin level needs to be confirmed with two measurements that&#xD;
                  are within 5 to 7 days of each other; (the second measurement must be obtained&#xD;
                  within 7 days prior to registration); both the first and second measurement must&#xD;
                  be =&lt; 2.5 x IULN; stability is defined as the second measurement being no more&#xD;
                  than one point higher than the first&#xD;
&#xD;
          -  Pancreatic cancer cohort specific criteria:&#xD;
&#xD;
               -  Patients must have unresectable or metastatic pancreatic cancer&#xD;
&#xD;
               -  Patients must have failed at least one prior line of therapy for metastatic or&#xD;
                  unresectable disease or have recurred within 6 months of completing adjuvant&#xD;
                  chemotherapy&#xD;
&#xD;
               -  Patients with liver metastases must have &lt; 50% involvement of the liver&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents&#xD;
&#xD;
          -  Patients must not be nursing due to the potential for congenital abnormalities and the&#xD;
             potential of this regimen to harm nursing infants&#xD;
&#xD;
          -  Any previous treatment with a hypomethylating agent, or with a PD1 or PD-L1 or&#xD;
             anti-PD-L2 or anti-CTLA4 inhibitor, including durvalumab (or any other antibody or&#xD;
             drug specifically targeting T-cell costimulation or checkpoint pathways); any&#xD;
             immunomodulatory agent that is not described above should be cleared by the principal&#xD;
             investigator (PI)&#xD;
&#xD;
          -  History of another primary malignancy except for:&#xD;
&#xD;
               -  Malignancy treated with curative intent and with no known active disease &gt;= 3&#xD;
                  years before the first dose of study drug&#xD;
&#xD;
               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence&#xD;
                  of disease&#xD;
&#xD;
               -  Adequately treated carcinoma in situ without evidence of disease eg, cervical&#xD;
                  cancer in situ&#xD;
&#xD;
               -  Controlled, superficial bladder carcinoma&#xD;
&#xD;
               -  T1a or T1b or T1c prostate carcinoma treated with radiation &gt;= 1 year prior to&#xD;
                  study enrollment and prostate specific antigen (PSA) within normal limits (WNL)&#xD;
                  since treatment&#xD;
&#xD;
               -  T2a or b prostate carcinoma treated curatively &gt;= 1 year prior to study&#xD;
                  enrollment and PSA undetectable since curative treatment&#xD;
&#xD;
               -  Other early stage cancers that have a minimal chance of recurrence (i.e stage I&#xD;
                  endometrial cancer, cervical cancer, etc.) may be cleared by the PI&#xD;
&#xD;
          -  Receipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy,&#xD;
             endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal&#xD;
             antibodies, other investigational agent) within 28 days prior to the first dose of&#xD;
             study drug and within 6 weeks for nitrosourea or mitomycin C&#xD;
&#xD;
          -  Mean QT interval corrected for heart rate (QTc) &gt;= 470 ms calculated from 3&#xD;
             electrocardiograms (ECGs) using Fridericia?s correction&#xD;
&#xD;
          -  Current or prior use of immunosuppressive medication within 28 days before the first&#xD;
             dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or&#xD;
             systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of&#xD;
             prednisone, or an equivalent corticosteroid; live attenuated vaccines within 30 days&#xD;
             of durvalumab dosing (ie, 30 days prior to the first dose, during treatment with&#xD;
             durvalumab and for 30 days post discontinuation of durvalumab); inactivated vaccines,&#xD;
             such as the injectable influenza vaccine, are permitted&#xD;
&#xD;
          -  Any unresolved toxicity Common Terminology Criteria for Adverse Events (CTCAE) grade 2&#xD;
             or more from previous anti-cancer therapy, except alopecia, hearing loss, peripheral&#xD;
             neuropathy or non-clinically significant laboratory abnormalities&#xD;
&#xD;
          -  Any prior grade &gt;= 3 immune-related adverse event (irAE) while receiving any previous&#xD;
             immunotherapy agent, or any unresolved irAE &gt; grade 1&#xD;
&#xD;
          -  Active or prior documented autoimmune disease; subjects with vitiligo, Grave?s&#xD;
             disease, or psoriasis not requiring systemic treatment (within the past 2 years) are&#xD;
             not excluded&#xD;
&#xD;
          -  Active or prior documented inflammatory bowel disease (e.g., Crohn?s disease,&#xD;
             ulcerative colitis)&#xD;
&#xD;
          -  History of primary immunodeficiency&#xD;
&#xD;
          -  History of allogeneic organ transplant&#xD;
&#xD;
          -  History of hypersensitivity to durvalumab, guadecitabine (SGI-110) or any excipient&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, uncontrolled hypertension (defined as&#xD;
             systolic blood pressure(SBP) &gt; 160 or diastolic blood pressure (DBP) &gt; 100 on 2&#xD;
             separate occasions separated by at least 24 hours), unstable angina pectoris, cardiac&#xD;
             arrhythmia, active peptic ulcer disease or gastritis, active bleeding diathesis&#xD;
             including any subject known to have evidence of human immunodeficiency virus (HIV), or&#xD;
             psychiatric illness/social situations that would limit compliance with study&#xD;
             requirements or compromise the ability of the subject to give written informed consent&#xD;
&#xD;
          -  Known history of previous clinical diagnosis of tuberculosis&#xD;
&#xD;
          -  History of leptomeningeal carcinomatosis or uncontrolled seizures&#xD;
&#xD;
          -  Receipt of live attenuated vaccination within 30 days prior to study entry or within&#xD;
             30 days of receiving durvalumab&#xD;
&#xD;
          -  Any condition that, in the opinion of the investigator, would interfere with&#xD;
             evaluation of study treatment or interpretation of patient safety or study results&#xD;
&#xD;
          -  Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive&#xD;
             of but not limited to surgery, radiation and/or corticosteroids&#xD;
&#xD;
          -  Presence of ascites that is not medically controlled or that required a therapeutic&#xD;
             paracentesis within the last 3 months prior to initiation of study therapy&#xD;
&#xD;
          -  Known history or ongoing diagnosis of pneumonitis&#xD;
&#xD;
          -  Hepatocellular carcinoma cohort specific exclusion criteria:&#xD;
&#xD;
               -  A history of hepatic encephalopathy within the past 12 months; patients on stable&#xD;
                  doses of lactulose for prophylaxis or as a result of previous hepatic&#xD;
                  encephalopathy (more than 12 months ago) are allowed (for HCC cohort only)&#xD;
&#xD;
               -  A history of bleeding esophageal or gastric varices within the last 6 months&#xD;
                  prior to initiation of study therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony El-Khoueiry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>August 19, 2017</study_first_submitted>
  <study_first_submitted_qc>August 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2017</study_first_posted>
  <last_update_submitted>April 5, 2023</last_update_submitted>
  <last_update_submitted_qc>April 5, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Gallbladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Guadecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03257761
org study id: 0S-16-18
secondary id: NCI-2017-01432
secondary id: 0S-16-18
secondary id: P30CA014089
nct id: NCT03257761
lead sponsor: 
collaborator: 
collaborator: 
has dmc: Yes
is fda regulated drug: Yes
is fda regulated device: No
This phase Ib trial studies the side effects and best dose of guadecitabine and how well it
      works when given together with durvalumab in treating patients with liver, pancreatic, bile
      duct, or gallbladder cancer that has spread to other places in the body. Guadecitabine may
      stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
      Monoclonal antibodies, such as durvalumab, may block tumor growth in different ways by
      targeting certain cells. Giving guadecitabine and durvalumab may work better in treating
      patients with liver, pancreatic, bile duct, or gallbladder cancer.
PRIMARY OBJECTIVES:

      I. To evaluate the dose limiting toxicities and determine the maximum tolerated
      dose/recommended phase 2 dose of the combination of guadecitabine and durvalumab. (Dose
      escalation part) II. To evaluate the objective response rate (per Response Evaluation
      Criteria in Solid Tumors [RECIST] 1.1) for the combination of guadecitabine and durvalumab in
      hepatocellular carcinoma, pancreatic cancer and cholangiocarcinoma cohorts, respectively.
      (Expansion part)

      SECONDARY OBJECTIVES:

      I. To describe the safety and tolerability of the combination of guadecitabine and
      durvalumab.

      II. To estimate the progression-free and overall survival of patients with advanced
      hepatocellular carcinoma (HCC), pancreatic cancer and biliary cancers treated with the
      combination of guadecitabine and durvalumab.

      TERTIARY OBJECTIVES:

      I. Correlate programmed cell death ligand 1 (PD-L1) and programmed cell death protein 1 (PD1)
      expression on various cells within tumor samples and anti-tumor effect (response rate and
      survival).

      II. Correlate effector T cells (Teff)/regulatory T cells (Treg) ratio in the tumor and
      anti-tumor effect.

      III. Correlate granulocytic and monocytic myeloid-derived suppressor cells (MDSCs) level in
      the peripheral blood using fluorescence-activated cell sorting (FACS) and anti-tumor effect.

      IV. Evaluate changes in inflammatory T cell signatures pre and post treatment and potential
      associations with anti-tumor effect.

      V. Assess the induction, activation, expansion and tumor infiltration of tumor
      neo-epitope-specific T cells.

      VI. Explore changes in gene methylation and expression with anti-tumor effect, with
      particular emphasis on the ancestry-informative marker (AIM) gene panel.

      VII. Correlate immunologic changes in pre- and post-treatment peripheral blood mononuclear
      cell (PBMCs) and anti-tumor effect.

      OUTLINE: This is a dose-escalation study of guadecitabine.

      Patients receive guadecitabine subcutaneously (SC) once daily (QD) on days 1-5 and durvalumab
      intravenously (IV) over 60 minutes on day 8. Courses repeat every 28 days in the absence of
      disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 2 months.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Incidence of adverse events
time frame: Up to 56 days
description: Graded according to Common Terminology Criteria for Adverse Events version 4.03.
measure: Tumor response (dose expansion)
time frame: Up to 2 years
description: Will be calculated by the percentage of patients having complete or partial response among all patients who have been treated at maximum tolerated dose/recommended phase II dose in each cohort. Will be assessed according to Response Evaluation Criteria in Solid Tumors (RECIST).
measure: Overall survival
time frame: From start of treatment until death due to any cause, assessed up to 2 years
description: Kaplan-Meier curves will be used to show overall survival in each cohort. Median overall survival and 95% confidence intervals will be derived from Kaplan-Meier curves.
measure: Progression-free survival
time frame: From start of treatment to time of progression per RECIST 1.1 or death whichever comes first, assessed up to 2 years
description: Kaplan-Meier curves will be used to show progression-free survival in each cohort. Median progression-free survival and 95% confidence intervals will be derived from Kaplan-Meier curves.
arm group label: Treatment (guadecitabine, durvalumab)
arm group type: Experimental
description: Patients receive guadecitabine SC QD on days 1-5 and durvalumab IV over 60 minutes on day 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
intervention type: Biological
intervention name: Durvalumab
description: Given IV
arm group label: Treatment (guadecitabine, durvalumab)
intervention type: Drug
intervention name: Guadecitabine
description: Given SC
arm group label: Treatment (guadecitabine, durvalumab)
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Anthony El-Khoueiry, MD
role: Principal Investigator
affiliation: University of Southern California
facility: 
facility: 
facility: 
country: United States
responsible party type: Sponsor
mesh term: Carcinoma
mesh term: Adenocarcinoma
mesh term: Pancreatic Neoplasms
mesh term: Carcinoma, Hepatocellular
mesh term: Cholangiocarcinoma
mesh term: Gallbladder Neoplasms
mesh term: Carcinoma, Ductal
mesh term: Recurrence
mesh term: Durvalumab
mesh term: Guadecitabine
sharing ipd: Undecided